Supplementary Table 1 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404) Article Swipe

View

Mamta Parikh , Nataliya V. Uboha , Naoko Takebe , Kit Tam , Philippe L. Bédard , Kari B. Wisinski , Arjun Mittra , Ming Yin , Yuanquan Yang , Anne M. Noonan , Julianne L. Holleran , Christopher Ruel , Paul Frankel , Jan H. Beumer , Edward M. Newman , Alexey V. Danilov , Steven D. Gore , Primo N. Lara ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.1158/2767-9764.30517914

Summary of Toxicity

Related Topics

Truth And Reconciliation Commission Of Canada

Concepts

No concepts available.

Metadata

Type: article
Landing Page: https://doi.org/10.1158/2767-9764.30517914
OA Status: gold
OpenAlex ID: https://openalex.org/W4415787381

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4415787381

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/2767-9764.30517914

Digital Object Identifier
Title: Supplementary Table 1 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

Work title
Type: article

OpenAlex work type
Publication year: 2025

Year of publication
Publication date: 2025-11-03

Full publication date if available
Authors: Mamta Parikh, Nataliya V. Uboha, Naoko Takebe, Kit Tam, Philippe L. Bédard, Kari B. Wisinski, Arjun Mittra, Ming Yin, Yuanquan Yang, Anne M. Noonan, Julianne L. Holleran, Christopher Ruel, Paul Frankel, Jan H. Beumer, Edward M. Newman, Alexey V. Danilov, Steven D. Gore, Primo N. Lara

List of authors in order
Landing page: https://doi.org/10.1158/2767-9764.30517914

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.1158/2767-9764.30517914

Direct OA link when available
Cited by: 0

Total citation count in OpenAlex

Full payload

id	https://openalex.org/W4415787381
doi	https://doi.org/10.1158/2767-9764.30517914
ids.doi	https://doi.org/10.1158/2767-9764.30517914
ids.openalex	https://openalex.org/W4415787381
fwci
type	article
title	Supplementary Table 1 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
is_xpac	False
apc_list
apc_paid
language
locations[0].id	doi:10.1158/2767-9764.30517914
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/2767-9764.30517914
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5005802303
authorships[0].author.orcid	https://orcid.org/0000-0002-7300-7452
authorships[0].author.display_name	Mamta Parikh
authorships[0].author_position	first
authorships[0].raw_author_name	Mamta Parikh
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5022835462
authorships[1].author.orcid	https://orcid.org/0000-0003-3449-1680
authorships[1].author.display_name	Nataliya V. Uboha
authorships[1].author_position	middle
authorships[1].raw_author_name	Nataliya V. Uboha
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5082874698
authorships[2].author.orcid	https://orcid.org/0000-0002-5790-4954
authorships[2].author.display_name	Naoko Takebe
authorships[2].author_position	middle
authorships[2].raw_author_name	Naoko Takebe
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5046103372
authorships[3].author.orcid	https://orcid.org/0009-0001-5392-4739
authorships[3].author.display_name	Kit Tam
authorships[3].author_position	middle
authorships[3].raw_author_name	Kit Tam
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5041145711
authorships[4].author.orcid	https://orcid.org/0000-0002-6771-2999
authorships[4].author.display_name	Philippe L. Bédard
authorships[4].author_position	middle
authorships[4].raw_author_name	Philippe L. Bedard
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5040571934
authorships[5].author.orcid	https://orcid.org/0000-0003-3535-0652
authorships[5].author.display_name	Kari B. Wisinski
authorships[5].author_position	middle
authorships[5].raw_author_name	Kari B. Wisinski
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5049013923
authorships[6].author.orcid	https://orcid.org/0000-0001-9572-3495
authorships[6].author.display_name	Arjun Mittra
authorships[6].author_position	middle
authorships[6].raw_author_name	Arjun Mittra
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5076225093
authorships[7].author.orcid	https://orcid.org/0000-0001-5743-4369
authorships[7].author.display_name	Ming Yin
authorships[7].author_position	middle
authorships[7].raw_author_name	Ming Yin
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5061950952
authorships[8].author.orcid	https://orcid.org/0000-0002-5209-9247
authorships[8].author.display_name	Yuanquan Yang
authorships[8].author_position	middle
authorships[8].raw_author_name	Yuanquan Yang
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5009849305
authorships[9].author.orcid	https://orcid.org/0000-0001-8083-8492
authorships[9].author.display_name	Anne M. Noonan
authorships[9].author_position	middle
authorships[9].raw_author_name	Anne M. Noonan
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5088208693
authorships[10].author.orcid	https://orcid.org/0000-0002-3738-8200
authorships[10].author.display_name	Julianne L. Holleran
authorships[10].author_position	middle
authorships[10].raw_author_name	Julianne L. Holleran
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5087409546
authorships[11].author.orcid	https://orcid.org/0000-0002-7205-0803
authorships[11].author.display_name	Christopher Ruel
authorships[11].author_position	middle
authorships[11].raw_author_name	Christopher Ruel
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5082853715
authorships[12].author.orcid	https://orcid.org/0000-0003-2231-6121
authorships[12].author.display_name	Paul Frankel
authorships[12].author_position	middle
authorships[12].raw_author_name	Paul Frankel
authorships[12].is_corresponding	False
authorships[13].author.id	https://openalex.org/A5027371881
authorships[13].author.orcid	https://orcid.org/0000-0002-8978-9401
authorships[13].author.display_name	Jan H. Beumer
authorships[13].author_position	middle
authorships[13].raw_author_name	Jan H. Beumer
authorships[13].is_corresponding	False
authorships[14].author.id	https://openalex.org/A5079414611
authorships[14].author.orcid	https://orcid.org/0000-0001-6988-5909
authorships[14].author.display_name	Edward M. Newman
authorships[14].author_position	middle
authorships[14].raw_author_name	Edward M. Newman
authorships[14].is_corresponding	False
authorships[15].author.id	https://openalex.org/A5067633124
authorships[15].author.orcid	https://orcid.org/0000-0003-4461-0970
authorships[15].author.display_name	Alexey V. Danilov
authorships[15].author_position	middle
authorships[15].raw_author_name	Alexey V. Danilov
authorships[15].is_corresponding	False
authorships[16].author.id	https://openalex.org/A5113251068
authorships[16].author.orcid	https://orcid.org/0009-0007-2139-5653
authorships[16].author.display_name	Steven D. Gore
authorships[16].author_position	middle
authorships[16].raw_author_name	Steven D. Gore
authorships[16].is_corresponding	False
authorships[17].author.id	https://openalex.org/A5075799959
authorships[17].author.orcid	https://orcid.org/0000-0001-9512-0002
authorships[17].author.display_name	Primo N. Lara
authorships[17].author_position	last
authorships[17].raw_author_name	Primo N. Lara
authorships[17].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.1158/2767-9764.30517914
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-11-03T00:00:00
display_name	Supplementary Table 1 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/2767-9764.30517914
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/2767-9764.30517914
primary_location.id	doi:10.1158/2767-9764.30517914
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/2767-9764.30517914
publication_date	2025-11-03
publication_year	2025
referenced_works_count	0
abstract_inverted_index.of	1
abstract_inverted_index.<p>Summary	0
abstract_inverted_index.Toxicity</p>	2
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	18
citation_normalized_percentile